Applied dna announces $3.44 million registered direct offering priced at-the-market under nasdaq rules

Stony brook, ny / accesswire / january 31, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, today announced that it has entered into securities purchase agreements (spas) with certain existing institutional investors (collectively the "holders") for the issuance and sale of an aggregate of 5,644,061 of its shares of common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.609 per share in a registered direct offering priced at-the-market under nasdaq rules. in a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 11,288,122 shares of its common stock.
APDN Ratings Summary
APDN Quant Ranking